Здоровье
Лекарство от иммунных расстройств от J&J завершило исследования средней и поздней стадии.
Johnson & Johnson’s experimental drug to treat two autoimmune diseases helped relieve symptoms when tested on adult patients in mid- and late-stage studies, the company
Комбинированный препарат Vertex для лечения муковисцидоза отвечает основным целям исследования
The company said that Vertex Pharmaceuticals’ experimental treatment for cystic fibrosis achieved all of its primary objectives in a late-stage study conducted in patients aged
Материнская компания Novo Nordisk купит Catalent за $16,5 млрд, чтобы увеличить предложение Wegovy
Novo Nordisk won a victory on Monday in the race to boost production of its popular obesity drug Wegovy, and its parent company announced it
Эйсай рассчитывает запустить в Китай 1500 пациентов с болезнью Альцгеймера
Eisai plans to roll out its pioneering Alzheimer’s disease drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly
Опубликованы первые данные о препарате для похудения Amgen
Data from Amgen’s animal studies and early-stage human trials of an experimental obesity drug published in a medical journal showed it promotes significant weight loss
Вальнева продала приоритетный ваучер на вакцину чикунгунья за $103 млн.
French vaccine maker Valneva said Monday it has sold a $103 million priority review voucher it received from the U.S. Food and Drug Administration. Valneva
Швейцарская школа гостеприимства закрывается из-за вспышки кори
The renowned Swiss hotel school Ecole Hoteliere de Lausanne has closed its Lausanne campus after cases of measles were detected among its students. “We have
AbbVie повышает прогноз продаж новых иммунологических препаратов до $27 миллиардов в 2027 году
AbbVie has raised its 2027 sales forecast for its immunology drugs Skyrizi and Rinvoq to $27 billion, up $6 billion from its previous forecast. The
Результаты испытаний показывают, что вторая вакцина против малярии обладает высокой защитной способностью
A malaria vaccine developed by Oxford University and the Indian Serum Institute prevented about three-quarters of symptomatic malaria cases in young children in the first
Biogen отказывается от препарата от Альцгеймера Адухельм
Biogen will complete a post-registration study of Aduhelm for the treatment of Alzheimer’s disease and regain licensing rights to the drug after failing to find